PL3672639T3 - Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego - Google Patents
Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwegoInfo
- Publication number
- PL3672639T3 PL3672639T3 PL19844315T PL19844315T PL3672639T3 PL 3672639 T3 PL3672639 T3 PL 3672639T3 PL 19844315 T PL19844315 T PL 19844315T PL 19844315 T PL19844315 T PL 19844315T PL 3672639 T3 PL3672639 T3 PL 3672639T3
- Authority
- PL
- Poland
- Prior art keywords
- ibrutinib
- bcl
- cancer
- inhibitor
- prevention
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000013066 combination product Substances 0.000 title 1
- 229940127555 combination product Drugs 0.000 title 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title 1
- 229960001507 ibrutinib Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810867251 | 2018-07-31 | ||
| PCT/CN2019/098252 WO2020024916A1 (en) | 2018-07-31 | 2019-07-30 | Combination product of bcl-2 inhibitor or bcl-2/bcl-xl dual inhibitor and btk inhibitor and use thereof in the prevention and/or treatment of diseases |
| EP19844315.2A EP3672639B1 (en) | 2018-07-31 | 2019-07-30 | Combination product of a bcl-2 inhibitor and ibrutinib for use in the prevention and/or treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3672639T3 true PL3672639T3 (pl) | 2022-05-09 |
Family
ID=69232343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19844315T PL3672639T3 (pl) | 2018-07-31 | 2019-07-30 | Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11478470B2 (pl) |
| EP (1) | EP3672639B1 (pl) |
| JP (1) | JP7085635B2 (pl) |
| KR (1) | KR20200138724A (pl) |
| CN (2) | CN110772521A (pl) |
| AU (1) | AU2019315487B2 (pl) |
| BR (1) | BR112020019189A2 (pl) |
| CA (1) | CA3094452C (pl) |
| EA (1) | EA202091965A1 (pl) |
| GE (1) | GEP20237508B (pl) |
| MX (1) | MX2020009758A (pl) |
| PL (1) | PL3672639T3 (pl) |
| TW (1) | TWI758623B (pl) |
| UA (1) | UA125199C2 (pl) |
| WO (1) | WO2020024916A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CN110772639B (zh) | 2018-07-31 | 2021-04-13 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途 |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| WO2021110097A1 (en) * | 2019-12-03 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| US20230078120A1 (en) * | 2020-05-04 | 2023-03-16 | Ascentage Pharma (Suzhou) Co.,Ltd. | Methods for Treating Coronavirus Infections |
| CN118161618A (zh) * | 2020-06-18 | 2024-06-11 | 苏州亚盛药业有限公司 | 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途 |
| CN115701997A (zh) * | 2020-08-10 | 2023-02-14 | 江苏恒瑞医药股份有限公司 | Btk抑制剂治疗疾病的用途 |
| US20230301989A1 (en) * | 2020-08-21 | 2023-09-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating systemic lupus erythematosus |
| CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
| JP2023550416A (ja) * | 2020-11-20 | 2023-12-01 | ベイジーン スウィッツァーランド ゲーエムベーハー | Ｂｔｋ阻害剤を用いて全身性エリテマトーデスを治療する方法 |
| CN114681458B (zh) * | 2020-12-28 | 2023-07-18 | 苏州亚盛药业有限公司 | 治疗多发性硬化症的方法 |
| IL308931A (en) * | 2021-06-02 | 2024-01-01 | Beigene Switzerland Gmbh | Methods for treating malignant B cells using a Bcl-2 inhibitor |
| WO2023011488A1 (zh) * | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| WO2023169357A1 (en) * | 2022-03-07 | 2023-09-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating immune diseases |
| TW202339721A (zh) * | 2022-03-31 | 2023-10-16 | 英屬開曼群島商百濟神州有限公司 | Bcl-xL抑制劑 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
| WO2008070663A2 (en) | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| PE20091180A1 (es) | 2007-12-27 | 2009-08-26 | Infinity Pharmaceuticals Inc | Tratamientos terapeuticos contra el cancer |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| EP3666758A1 (en) | 2008-12-05 | 2020-06-17 | AbbVie Inc. | Process for the preparation of a sulfonamide derivative |
| JP2012517241A (ja) | 2009-02-11 | 2012-08-02 | アボット・ラボラトリーズ | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
| DK2435432T6 (da) | 2009-05-26 | 2023-12-18 | Abbvie Ireland Unlimited Co | Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| DK2642999T3 (en) | 2010-11-23 | 2017-01-09 | Abbvie Ireland Unlimited Co | METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS |
| KR101923364B1 (ko) | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
| JP5998152B2 (ja) | 2011-01-25 | 2016-09-28 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法 |
| CA2897055C (en) * | 2013-01-16 | 2021-04-20 | The Regents Of The University Of Michigan | Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| US9925192B2 (en) | 2014-02-28 | 2018-03-27 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| AU2015247646B2 (en) | 2014-04-17 | 2019-06-06 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
| HUE056329T2 (hu) * | 2014-08-11 | 2022-02-28 | Acerta Pharma Bv | BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| TW201717953A (zh) * | 2015-08-03 | 2017-06-01 | 基利科學股份有限公司 | 用於治療癌症之組合療法 |
| CN105061315B (zh) | 2015-08-06 | 2017-10-24 | 大连理工大学 | 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用 |
| US20190060309A1 (en) | 2015-08-28 | 2019-02-28 | Novartis Ag | Mdm2 inhibitors and combinations thereof |
| EP3569601B1 (en) * | 2016-08-05 | 2022-06-22 | The Regents of The University of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| CN110772639B (zh) | 2018-07-31 | 2021-04-13 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途 |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| AU2019385458A1 (en) | 2018-11-23 | 2021-01-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and use thereof |
-
2019
- 2019-07-22 CN CN201910660208.9A patent/CN110772521A/zh active Pending
- 2019-07-22 CN CN202210270632.4A patent/CN114522167A/zh active Pending
- 2019-07-30 TW TW108126939A patent/TWI758623B/zh active
- 2019-07-30 MX MX2020009758A patent/MX2020009758A/es unknown
- 2019-07-30 KR KR1020207026502A patent/KR20200138724A/ko not_active Application Discontinuation
- 2019-07-30 PL PL19844315T patent/PL3672639T3/pl unknown
- 2019-07-30 US US16/648,603 patent/US11478470B2/en active Active
- 2019-07-30 BR BR112020019189-2A patent/BR112020019189A2/pt not_active IP Right Cessation
- 2019-07-30 EA EA202091965A patent/EA202091965A1/ru unknown
- 2019-07-30 GE GEAP201915448A patent/GEP20237508B/en unknown
- 2019-07-30 JP JP2020550152A patent/JP7085635B2/ja active Active
- 2019-07-30 UA UAA202005949A patent/UA125199C2/uk unknown
- 2019-07-30 CA CA3094452A patent/CA3094452C/en active Active
- 2019-07-30 WO PCT/CN2019/098252 patent/WO2020024916A1/en unknown
- 2019-07-30 AU AU2019315487A patent/AU2019315487B2/en active Active
- 2019-07-30 EP EP19844315.2A patent/EP3672639B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11478470B2 (en) | 2022-10-25 |
| EP3672639A1 (en) | 2020-07-01 |
| EA202091965A1 (ru) | 2021-05-14 |
| GEP20237508B (en) | 2023-05-25 |
| JP2021523091A (ja) | 2021-09-02 |
| AU2019315487B2 (en) | 2022-07-14 |
| KR20200138724A (ko) | 2020-12-10 |
| UA125199C2 (uk) | 2022-01-26 |
| BR112020019189A2 (pt) | 2021-02-09 |
| TWI758623B (zh) | 2022-03-21 |
| WO2020024916A1 (en) | 2020-02-06 |
| TW202007396A (zh) | 2020-02-16 |
| AU2019315487A1 (en) | 2020-10-01 |
| CN114522167A (zh) | 2022-05-24 |
| CA3094452A1 (en) | 2020-02-06 |
| US20200222393A1 (en) | 2020-07-16 |
| MX2020009758A (es) | 2020-10-08 |
| CN110772521A (zh) | 2020-02-11 |
| JP7085635B2 (ja) | 2022-06-16 |
| CA3094452C (en) | 2023-02-21 |
| EP3672639A4 (en) | 2020-09-30 |
| EP3672639B1 (en) | 2022-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3672639T3 (pl) | Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego | |
| EP3672594A4 (en) | COMBINATION PRODUCT OF BCL-2-INHIBITOR AND MDM2-INHIBITOR AND USE THEREOF FOR THE PREVENTION AND / OR TREATMENT OF DISEASES | |
| EP3672595A4 (en) | COMBINATION PRODUCT OF A BCL-2 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND ASSOCIATED USE IN THE PREVENTION AND / OR TREATMENT OF DISEASES | |
| IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
| HK1259545A1 (zh) | 用於治療癌症的bcl-2抑制劑和mek抑制劑組合產品 | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| EP3843751A4 (en) | BCL-2/BCL-XL INHIBITOR AND CHEMOTHERAPEUTIC COMBINATION PRODUCT AND USE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DISEASE | |
| IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
| IL280475A (en) | A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for the treatment or prevention of a C5-related disease | |
| IL265961A (en) | Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing | |
| HK1257239A1 (zh) | 預防和治療肥胖症的藥物及其用途 | |
| IL289758A (en) | Proportin inhibitors for use in the prevention and treatment of kidney damage | |
| IL283937A (en) | Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment | |
| SG11202107720UA (en) | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer | |
| IL290656A (en) | Lorbinectadine in the treatment of malignant mesothelioma | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| SI3969000T1 (sl) | Bcl-2 inhibitorji za uporabo pri zdravljenju z Bcl-2 posredovanega raka, ki nosi mutacijo Gly101Val | |
| IL268860A (en) | Granzyme B inhibitor preparations and methods for preventing and/or treating blistered and/or peeling skin | |
| HK1246205A1 (zh) | 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合 | |
| HUP1900281A1 (hu) | Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra | |
| PT3969000T (pt) | Inibidores de bcl-2 para utilização no tratamento de um cancro mediado por bcl-2 que transporta a mutação gly101val | |
| PL3813843T3 (pl) | Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego | |
| EP3829564C0 (en) | CURCUMIN AND HOMOTAURINE FOR USE IN THE PREVENTION OR TREATMENT OF FORMS OF COGNITIVE DECLINE | |
| AU2019902712A0 (en) | Inhibitors and use thereof in cancer treatment | |
| IL286326A (en) | Azetidobenzodiazepine dimers and conjugates containing them for use in cancer therapy |